Tocilizumab for severe COVID-19: a systematic review and meta-analysis

Review concludes that there is no conclusive evidence that tocilizumab provides additional benefit for severe COVID-19.
Review concludes that there is no conclusive evidence that tocilizumab provides additional benefit for severe COVID-19.